Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321854 · ClinicalTrials.gov registry record · Phase 4
Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 535
- Enrollment target
NCT00321854 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 535 participants.
The verdict
NCT00321854, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 535 participants
- Enrollment target
Study Summary
This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease
Interventions
- DRUG pramipexole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2006-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00321854
The ClinicalTrials.gov registry entry for NCT00321854 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 535 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pramipexole is the first listed.
NCT00321854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00321854 about?
NCT00321854 is a clinical study titled "Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)". This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease
What is the current status of trial NCT00321854?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 535 participants. The study started on 2006-05.
What interventions are being tested in trial NCT00321854?
The interventions under investigation include: pramipexole (DRUG).
Who is sponsoring clinical trial NCT00321854?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.